Table 1 Relationship between RPRD1A protein expression and clinicopathologic characteristics (n = 267).
From: RPRD1A stabilizes NRF2 and aggravates HCC progression through competing with p62 for TRIM21 binding
Characteristics | No. patients | RPRD1A immunoreactivity | P value | |
|---|---|---|---|---|
(%) | Low | High | ||
Age, year | 0.073 | |||
≤49 | 149 (55.8) | 91 | 58 | |
>49 | 118 (44.2) | 83 | 35 | |
Gender | 0.12 | |||
Male | 234 (87.6) | 149 | 85 | |
Female | 33 (12.4) | 25 | 8 | |
HBs Ag | 0.372 | |||
Negative | 20 (7.5) | 14 | 6 | |
Positive | 247 (92.5) | 161 | 86 | |
Tumor size (cm) | 0.011 | |||
≤5 | 46 (17.2) | 37 | 9 | |
>5 | 221 (82.8) | 137 | 84 | |
Tumor number | 0.342 | |||
Single | 245 (91.8) | 161 | 84 | |
Multiple | 22 (8.2) | 13 | 9 | |
AFP (ng/mL) | 0.5 | |||
≤400 | 79 (29.6) | 51 | 28 | |
>400 | 188 (70.4) | 123 | 65 | |
Invasion | 0.121 | |||
Negative | 183 (68.5) | 124 | 59 | |
Positive | 84 (31.5) | 50 | 34 | |
BCLC stage | 0. 010 | |||
A | 39 (14.6) | 33 | 6 | |
B | 71 (26.6) | 48 | 23 | |
C | 157 (58.8) | 93 | 64 | |
Portal vein tumor emboli (PVTT) | 0.008 | |||
Negative | 111 (41.6) | 82 | 29 | |
Positive | 156 (58.4) | 92 | 64 | |
Microscopic portal vein tumor thrombus (MI-PVTT) | 0.025 | |||
Negative | 29 (10.9) | 24 | 5 | |
Positive | 238 (89.1) | 150 | 88 | |
TNM stage | 0.001 | |||
I & II | 90 (33.7) | 72 | 18 | |
III & IV | 177 (66.3) | 102 | 75 | |
NRF2 staining | 0.019 | |||
Low | 86 (32.2) | 64 | 22 | |
High | 181 (67.8) | 110 | 71 | |
